Palatin Technologies, Inc. (NYSEMKT:PTN) is in the final phase of advancing its female libido drug ‘Bremelanotide’, and the market is huge. The stock currently seems undervalued and could jump 100% in value within next one year. Bremelanotide is distinguished from Addyi as well as effective and safer as known from the Phase III results. FDA nod is extremely possible as per the FDA’s own model.
Palatin is a late-stage biotech firm providing investors an opportunity to gain from a rare market misunderstanding – probably earning returns of more than 100% in the imminent year from a buyout, FDA nod or without a catalyst. In the long-term, many experts have set a price target of $6.00-$7.00 on PTN currently trading around $0.44.
The company owns Bremelanotide rights, a peptide that functions on the melanocortin receptors in the brain to surge libido. Bremelanotide was advanced for the cure of Female HSDD. It is vital to record that, unlike Addyi, the peptide has been shown to work on men, and the initial assessment of this compound are impressive.
Depending on the anecdotal testimonials of the users who have tried this medication, previously available via peptide websites and in Melanotan, there is serious problem for this medication to take the throne from Viagra in the cure of male sexual dysfunction, an industry worth billions.
Besides the probability of use in men, Bremelanotide at present has a cult following. Many patients seek help for ejaculatory anhedonia, anorgasmia and PSSD. Some of these problems are comorbid with, or the reason behind, female HSDD. Many patients suffering from these problem find Bremelanotide as the sole feasible treatment.
Palatin ended its phase III trials on the drug. Safety and efficacy is demonstrated, and Bremelanotide surpasses Valeant’s Addyi, which is the only approved drug in both metrics. Bremelanotide only needs to be consumed before sexual activity.